Non-receptor tyrosine kinase signaling in autoimmunity and therapeutic implications

Authors

Sabrina Solouki, Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA.
Avery August, Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA. Electronic address: averyaugust@cornell.edu.
Weishan Huang, Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA; Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA. Electronic address: huang1@lsu.edu.

Document Type

Article

Publication Date

9-1-2019

Abstract

Autoimmune diseases are characterized by impaired immune tolerance towards self-antigens, leading to enhanced immunity to self by dysfunctional B cells and/or T cells. The activation of these cells is controlled by non-receptor tyrosine kinases (NRTKs), which are critical mediators of antigen receptor and cytokine receptor signaling pathways. NRTKs transduce, amplify and sustain activating signals that contribute to autoimmunity, and are counter-regulated by protein tyrosine phosphatases (PTPs). The function of and interaction between NRTKs and PTPs during the development of autoimmunity could be key points of therapeutic interference against autoimmune diseases. In this review, we summarize the current state of knowledge of the functions of NRTKs and PTPs involved in B cell receptor (BCR), T cell receptor (TCR), and cytokine receptor signaling pathways that contribute to autoimmunity, and discuss their targeting for therapeutic approaches against autoimmune diseases.

Publication Source (Journal or Book title)

Pharmacology & therapeutics

First Page

39

Last Page

50

Recommended Citation

Solouki, S., August, A., & Huang, W. (2019). Non-receptor tyrosine kinase signaling in autoimmunity and therapeutic implications. Pharmacology & therapeutics, 201, 39-50. https://doi.org/10.1016/j.pharmthera.2019.05.008